D.A. Davidson & CO. cut its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 6.6% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 23,476 shares of the company’s stock after selling 1,646 shares during the period. D.A. Davidson & CO.’s holdings in AstraZeneca were worth $1,627,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Contravisory Investment Management Inc. grew its position in AstraZeneca by 11.1% in the 1st quarter. Contravisory Investment Management Inc. now owns 1,429 shares of the company’s stock worth $99,000 after purchasing an additional 143 shares during the period. Oppenheimer & Co. Inc. increased its position in AstraZeneca by 1.5% during the fourth quarter. Oppenheimer & Co. Inc. now owns 11,186 shares of the company’s stock valued at $758,000 after acquiring an additional 166 shares during the last quarter. Arete Wealth Advisors LLC boosted its position in AstraZeneca by 11.4% in the fourth quarter. Arete Wealth Advisors LLC now owns 12,222 shares of the company’s stock worth $828,675,870,000 after purchasing an additional 1,251 shares during the last quarter. Foster Victor Wealth Advisors LLC bought a new stake in shares of AstraZeneca during the 4th quarter valued at about $239,000. Finally, ARGI Investment Services LLC increased its position in shares of AstraZeneca by 2.6% during the 4th quarter. ARGI Investment Services LLC now owns 7,261 shares of the company’s stock valued at $492,000 after purchasing an additional 187 shares during the last quarter. Hedge funds and other institutional investors own 16.07% of the company’s stock.
AstraZeneca Stock Performance
NASDAQ:AZN opened at $66.47 on Thursday. The company has a debt-to-equity ratio of 0.75, a current ratio of 0.90 and a quick ratio of 0.70. The company has a market cap of $206.04 billion, a price-to-earnings ratio of 43.73, a PEG ratio of 1.31 and a beta of 0.50. AstraZeneca PLC has a 1 year low of $52.65 and a 1 year high of $76.56. The stock’s 50 day simple moving average is $72.10 and its two-hundred day simple moving average is $70.29.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on AZN. UBS Group upgraded shares of AstraZeneca from a “neutral” rating to a “buy” rating in a research note on Wednesday. Deutsche Bank Aktiengesellschaft lowered AstraZeneca from a “buy” rating to a “hold” rating in a report on Tuesday, July 4th. Morgan Stanley raised AstraZeneca from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, April 11th. StockNews.com began coverage on shares of AstraZeneca in a report on Thursday, May 18th. They issued a “strong-buy” rating for the company. Finally, Argus lowered their price target on shares of AstraZeneca from $85.00 to $80.00 in a report on Friday, May 26th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $103.00.
AstraZeneca Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
Featured Stories
- Five stocks we like better than AstraZeneca
- Contrarian Play: Beyond Meat Is At An Inflection Point
- Alibaba Just Flashed Green, Very Green
- This Small Cap Stock Surged Over 100%
- The CPI Data Isn’t As Good As You Think It Is
- How to Invest in Gold and Silver
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.
